ClearPoint Neuro Reports Second Quarter 2022 Results

Record Quarterly Revenue Achieved; Company Reaffirms 2022 Revenue Forecast

SOLANA BEACH, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its second quarter ended June 30, 2022.

Second Quarter Highlights

  • Reported record quarterly revenue of $5.2 million, a 52% year-over-year increase;
  • Partner PTC Therapeutics received a positive opinion for its gene therapy treatment Upstaza™. from the European Medicines Agency’s Committee for Medicinal Products for Human Use. Upstaza, which was granted full marketing authorization by the European Commission in July 2022, will be administered with the Company’s SmartFlow® Neuro Cannula;
  • Increased biologics and drug delivery revenue to $2.4 million, a 73% year-over-year increase;
  • Added multiple new biologics and drug delivery partners in the quarter to bring the total to more than 45;
  • Installed four additional systems in the quarter bringing the total to 8 new installations year-to-date;
  • Achieved Medical Device Single Audit Program (MDSAP) certification paving the way for additional international regulatory submissions in support of pharmaceutical partners; and
  • Cash and short-term investments totaled $45.1 million as of June 30, 2022.

Business Outlook

  • The Company reaffirms its full year 2022 revenue outlook of between $21.0 and $22.0 million.

“The ClearPoint Neuro Team has continued to execute against our four-pillar growth strategy in the second quarter,” commented Joe Burnett, President and CEO. “We achieved another record quarter for revenue and over 50% growth despite an elevated case cancellation rate and supply chain disruptions. Our biologics and drug delivery business led the way and became our largest segment with product and service revenue growing at more than 70%. The team also added multiple new pharma and academic partners bringing our total to more than 45 and keeping pace at approximately one new partner each month. Our ClearPoint Navigation system was installed at four additional centers bringing the total new centers to eight in 2022 across the U.S. and Europe. Our product development team continues to execute on our pipeline and has additional products being reviewed by global regulatory bodies.

Particularly of note, the European Commission granted marketing authorization for Upstaza to our partner PTC Therapeutics. Upstaza is the first gene therapy approved anywhere in the world to be dosed by direct infusion into the brain. Consistent with our long term strategy, the Summary of Product Characteristics for Upstaza specifically includes the ClearPoint SmartFlow Neuro Cannula as the device used for minimally invasive infusion of the gene therapy. We believe the approval of Upstaza, delivered with ClearPoint’s cannula, demonstrates the viability and potential of our drug delivery partnerships.

At present, we are reaffirming our prior guidance of revenue between $21.0 and $22.0 million for the year.”

Financial Results – Quarter Ended June 30, 2022

Total revenue was $5.2 million for the three months ended June 30, 2022, and $3.4 million for the three months ended June 30, 2021, which represents an increase of $1.8 million, or 52%.

Functional neurosurgery navigation and therapy revenue, increased 17% to $2.2 million for the three months ended June 30, 2022, from $1.9 million for the same period in 2021. The growth was driven by higher service revenue.

Biologics and drug delivery revenue, which includes sales of disposable products and services related to customer-sponsored clinical trials utilizing our products, increased 73% to $2.4 million for the three months ended June 30, 2022, from $1.4 million for the same period in 2021. This increase is attributable to a $0.8 million increase in product revenue and $0.2 million increase in service revenue.

Capital equipment and software revenue, consisting of sales of ClearPoint reusable hardware and software, and of related services, increased 282% to $0.6 million for the three months ended June 30, 2022, from $0.2 million for the same period in 2021 due to an increase in the sale of ClearPoint systems.

Gross margin for the three months ended June 30, 2022, was 63%, as compared to a gross margin of 67%, for the three months ended June 30, 2021. The decrease in gross margin was due primarily to an increase in overhead expenses, excess and obsolete reserves, and product mix.

Operating expenses for the second quarter of 2022 were $7.5 million, compared to $5.7 million for the second quarter of 2021. The increase was mainly driven by the increase in headcount across the organization, product development expenses and share based compensation.

At June 30, 2022, the Company had cash and cash equivalents and short-term investments totaling $45.1 million as compared to $54.1 million at December 31, 2021, with the decrease resulting primarily from the use of cash in operating activities of $9.3 million.

Teleconference Information

Investors and analysts are invited to listen to a live broadcast review of the Company's 2022 second quarter on Tuesday, August 9, 2022 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here: Investors and analysts who would like to participate in the conference call via telephone may do so at (888) 437-3179, or at (404) 267-0369 if calling from outside the U.S. or Canada.

For those who cannot access the live broadcast, a replay will be available shortly after the completion of the call until September 9, 2022, by calling (877) 660-6853, or (201) 612-7415 if calling from outside the U.S. or Canada, and then entering conference I.D. number 413671. An online archive of the broadcast will be available on the Company's Investor website at

About ClearPoint Neuro

ClearPoint Neuro’s mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of the Company’s current product portfolio include deep brain stimulation, laser ablation, biopsy, neuro-aspiration, and delivery of drugs, biologics, and gene therapy to the brain. The ClearPoint® Neuro Navigation System has FDA clearance, is CE-marked, and is installed in over 60 active sites in the United States, Canada, and Europe. ClearPoint Neuro is partnered with more than 45 pharmaceutical and biotech companies, academic institutions, and contract research organizations providing solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide. To date, more than 5,000 cases have been performed and supported by the Company’s field-based clinical specialist team, which offers support and services to our customers and partners worldwide. For more information, please visit

Forward-Looking Statements

Statements in this press release and in the teleconference referenced above concerning the Company’s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the impact of the COVID-19 pandemic and the measures adopted to contain its spread; future revenue from sales of the Company’s ClearPoint Neuro Navigation System products; the Company’s ability to market, commercialize and achieve broader market acceptance for the Company’s ClearPoint Neuro Navigation System products; the ability of our biologics and drug delivery partners to achieve commercial success, including their use of our products and services in their delivery of therapies; and risks inherent in the research and development of new products. More detailed information on these and additional factors that could affect the Company’s actual results are described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, and the Company’s Quarterly Report on Form 10-Q for the three months ended March 31, 2022, both of which have been filed with the Securities and Exchange Commission, and the Company’s Quarterly Report on Form 10-Q for the three months ended June 30, 2022, which the Company intends to file with the Securities and Exchange Commission on or before August 15, 2022.

Consolidated Statements of Operations
(Dollars in thousands, except for per share data)

 For The Three Months Ended June 30,
 2022 2021
Product revenue$3,457  $2,363 
Service and other revenue 1,743   1,050 
Total revenue 5,200   3,413 
Cost of revenue 1,943   1,139 
Gross profit 3,257   2,274 
Research and development costs 2,284   2,109 
Sales and marketing expenses 2,187   1,590 
General and administrative expenses 2,990   1,982 
Operating loss (4,204)  (3,407)
Other expense:   
Other expense, net (8)  (96)
Interest expense, net (91)  (240)
Net loss$(4,303) $(3,743)
Net loss per share attributable to common stockholders:   
Basic and diluted$(0.18) $(0.17)
Weighted average shares used in computing net loss per share:   
Basic and diluted 23,985,577   21,523,393 

 For The Six Months Ended June 30,
Product revenue$6,620  $5,525 
Service and other revenue 3,611   1,918 
Total revenue 10,231   7,443 
Cost of revenue 3,728   2,555 
Gross profit 6,503   4,888 
Research and development costs 4,817   3,673 
Sales and marketing expenses 4,032   3,165 
General and administrative expenses 5,722   3,638 
Operating loss (8,068)  (5,588)
Other expense:   
Other income (expense), net 3   (122)
Interest expense, net (197)  (571)
Net loss$(8,262) $(6,281)
Net loss per share attributable to common stockholders:   
Basic and diluted$(0.35) $(0.31)
Weighted average shares used in computing net loss per share:   
Basic and diluted 23,834,847   20,195,488 

Consolidated Balance Sheets
(Dollars in thousands, except for per share data)

 June 30, 
 December 31, 
Current assets:   
Cash and cash equivalents$23,524  $54,109 
Short-term investments 21,613    
Accounts receivable, net 3,348   2,337 
Inventory, net 6,639   4,938 
Prepaid expenses and other current assets 1,517   508 
Total current assets 56,641   61,892 
Property and equipment, net 689   539 
Operating lease rights of use 1,992   2,241 
Software license inventory 504   519 
Licensing rights 320   265 
Other assets 94   125 
Total assets$60,240  $65,581 
Current liabilities:   
Accounts payable$1,592  $427 
Accrued compensation 1,814   2,604 
Other accrued liabilities 870   537 
Operating lease liabilities, current portion 532   507 
Deferred product and service revenue, current portion 675   678 
Total current liabilities 5,483   4,753 
Operating lease liabilities, net of current portion 1,671   1,939 
Deferred product and service revenue, net of current portion 401   264 
2020 senior secured convertible notes payable, net 9,865   9,838 
Total liabilities 17,420   16,794 
Commitments and contingencies   
Stockholders’ equity:   
Preferred stock, $0.01 par value; 25,000,000 shares authorized; none issued and outstanding at June 30, 2022 and December 31, 2021     
Common stock, $0.01 par value; 200,000,000 shares authorized; 24,480,600 shares issued and outstanding at June 30, 2022; and 23,665,991 issued and outstanding at December 31, 2021 245   237 
Additional paid-in capital 184,769   182,482 
Accumulated deficit (142,194)  (133,932)
Total stockholders’ equity 42,820   48,787 
Total liabilities and stockholders’ equity$60,240  $65,581 

Consolidated Statements of Cash Flows
(Dollars in thousands)

 For The Six Months Ended June 30,
Cash flows from operating activities:   
Net loss$(8,262) $(6,281)
Adjustments to reconcile net loss to net cash flows from operating activities:   
Allowance for doubtful accounts (10)  92 
Depreciation and amortization 187   62 
Share-based compensation 1,779   567 
Payment-in-kind interest    189 
Amortization of debt issuance costs and original issue discounts 27   54 
Amortization of lease rights of use, net of accretion in lease liabilities 267   267 
Accretion of discounts on short-term investments (23)   
Increase (decrease) in cash resulting from changes in:   
Accounts receivable (1,001)  (617)
Inventory, net (1,786)  (304)
Prepaid expenses and other current assets (1,010)  (760)
Other assets 30   (93)
Accounts payable and accrued expenses 679   1,312 
Lease liabilities (261)  (195)
Deferred revenue 134   (142)
Net cash flows from operating activities (9,250)  (5,849)
Cash flows from investing activities:   
Purchases of property and equipment (145)  (5)
Acquisition of licensing rights (116)   
Purchase of short-term investments (21,590)   
Net cash flows from investing activities (21,851)  (5)
Cash flows from financing activities:   
Proceeds from public offering of common stock, net of offering costs    46,785 
Proceeds from stock option and warrant exercises 256   494 
Proceeds from issuance of common stock under employee stock purchase plan 260    
Net cash flows from financing activities 516   47,279 
Net change in cash and cash equivalents (30,585)  41,425 
Cash and cash equivalents, beginning of period 54,109   20,099 
Cash and cash equivalents, end of period$23,524  $61,524 
Cash paid for:   
Income taxes$  $ 
Interest$207  $353 


Contact Data